I disse dager hvor vi diskuterer mulig avtale med AZ så er det kanskje greit om vi tar en oppgang hvordan PCI Biotech har prøvd å sikre seg retten til bruk av teknologien.
Oppsummert så har jeg funnet:
11 innvilgede patenter
6 som kan bli godkjent når som helst…
Av de seks som er under vurdering, så stammer 4 fra tidsrommet 2016 til 2018 (publisering) og jeg antar det vil følge med en børsmelding om de går gjennom (ref Per som også venter på avklaring).
https://patents.justia.com/patent/20180050105
https://patents.justia.com/patent/20170143811
https://patents.justia.com/patent/20160206725
https://patents.justia.com/patent/20160040128
De resterende to er fra 2011 og 2009.
La oss tenke oss at vi sitter i AZ management og ser på gamle studier, pågående studier, egne studier samt PCIB sitt patent bibliotek med opsjon på at seks andre kan gå gjennom. I tillegg kan det være flere, siden publisering skjer kun etter 18mnd fra innlevering. Kjøperen, hvem nå enn det blir får tilgang til denne unike patent-poolen samtidig så nærmer vi oss mulig markedstilgang. I tillegg så har vårt unike team vært innvolvert i utrolig mye som enda ikke er patentert / publisert …
La oss ta en enkel sammenlikning - NANO. NANO har kun to patenter som stammer fra 2014/2016. De har ikke flere «publication» av det jeg kan se. Tror Roy har hoppet videre : ).
Patenter
Compound and method
https://patents.justia.com/patent/10537639 Date of Patent : Jan 21, 2020
The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of a cell using a photochemical internalization method in which a cytokine, preferably GM-CSF, is used to enhance the method. The method may be used to stimulate an immune response and for various therapeutic or prophylactic methods…
Antigen delivery device and method
https://patents.justia.com/patent/10166401 Date of Patent : Jan 1, 2019
A device for activating light-induced rupture of endocytic vesicles in target cells of a patient so as to effect delivery of an administered antigen to cytosol in the target cells, is described. The device is adapted to be worn by a patient over a region of skin where an antigen and a photosensitising agent are to be administered. The device comprises a rear surface that is rounded or otherwise configured to be worn against the patient’s skin…
Method of stimulating an immune response
https://patents.justia.com/patent/9737594 Date of Patent : Aug 22, 2018
The present invention provides a method of stimulating an immune response to an antigenic molecule, by contacting a cell with the antigenic molecule and with a photosensitizing agent, irradiating the cell, and thereby presenting the antigenic molecule, or part thereof, on the surface of said cell and stimulating an immune response.
Conjugate of a photosensitiser and chitosan and uses thereof
https://patents.justia.com/patent/9901636 Date of Patent : Feb 27, 2018
The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitizing agent, and uses thereof in photochemical internalization (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.
Method for introducing siRNA into cells by photochemical internalisation
https://patents.justia.com/patent/9700622 Date of Patent : Jul 11, 2017
The present invention relates to a method for introducing an siRNA molecule into the cytosol of a cell, said method comprising i) contacting said cell with an siRNA molecule, a carrier and a photosensitizing agent, and ii) irradiating the cell with light of a wavelength effective to activate the photosensitizing agent, wherein said carrier comprises a cationic polyamine such as a lipopolyamine in a non-liposomal formulation, polyethyleneimine (PEI), a betacyclodextrin amine polymer, an amine group containing dendrimer, and a cationic peptide.
Photochemical internalisation of kinase inhibitors
https://patents.justia.com/patent/9241996 Date of Patent : Jan 26, 2016
The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect.
Photosensitizing compositions
https://patents.justia.com/patent/9026203 Date of Patent : May 5, 2015
The invention relates to pharmaceutically acceptable salts of amphiphilic photosensitizing agents which have a water solubility of at least 0.5 mg/ml and to their use in methods of photochemical internalization. Such salts may be formed from a pharmaceutically acceptable base, for example an organic amine such as an amino alcohol, or from a pharmaceutically acceptable acid, for example a sulphonic acid or a sulphonic acid derivative.
Method of vaccination
https://patents.justia.com/patent/8216587 Date of Patent : Jul 10, 2012
The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.
Compound
https://patents.justia.com/patent/8096419 Date of Patent : Jan 17, 2012
he present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula I: (wherein X is —SO3H; n, p, q and r are each independently 0 or 1; and the sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, e.g. 2 or 4) isomers and isomer mixtures thereof. The compounds of the invention and their pharmaceutically acceptable salts find particular use as photosensitizing agents in the photochemical internalization of molecules and in photodynamic therapy.
PHOTOCHEMICAL INTERNALIZATION FOR DELIVERY OF MOLECULES INTO THE CYTOSOL
https://patents.justia.com/patent/20070274953 Date of Patent : Aug 30, 2011
The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.
Photochemical internalization for virus-mediated molecule delivery into the cyosol
https://patents.justia.com/patent/7521239 Date of Patent : Apr 21, 2009
A method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitizing agent, the cell is irradiated with light of a wavelength effective to activate the photosensitizing agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.
La oss håpe det kommer melding snarlig, men vi bør ha is i magen